Payment overview · 2025
General Payments
$765.56
24 reported records · 8 companies
Healthcare provider profile · identity verified
Narinder Dawar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SMITHTOWN, NY · NPI 1750651238
Verified facts
What the public records show
CMS Open Payments records show Narinder Dawar, MD received $765.56 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rexulti.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Eliquis by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $336.77 | 44.0% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $250.00 | 32.7% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $65.27 | 8.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.34 | 5.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.15 | 2.9% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.56 | 2.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.08 | 2.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.39 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $765.56 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $315.56 | 13 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $285.34 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $210.21 | 9 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $209.20 | 9 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $65.27 | 2 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| CALDOLOR Normalized: caldolor |
Drug | Cumberland Pharmaceuticals, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 324 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
324 | 42 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
324 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 416 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 41 |
| Potassium Chloride | Potassium Chloride | 376 | 41 |
| Eliquis | Apixaban | 324 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 293 | 21 |
| Gabapentin | Gabapentin | 265 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 21 |
| Mirtazapine | Mirtazapine | 145 | 18 |
| Metformin Hcl | Metformin Hcl | 143 | 17 |
| Warfarin Sodium | Warfarin Sodium | 133 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 17 |
| Sertraline Hcl | Sertraline Hcl | 126 | 12 |
| Losartan Potassium | Losartan Potassium | 123 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 15 |
| Lisinopril | Lisinopril | 114 | 12 |
| Levetiracetam | Levetiracetam | 109 | 14 |
| Famotidine | Famotidine | 108 | 28 |
| Gemtesa | Vibegron | 101 | suppressed |
| Nystatin | Nystatin | 99 | 18 |
| Donepezil Hcl | Donepezil Hcl | 92 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 14 |
| Baclofen | Baclofen | 86 | suppressed |
| Allopurinol | Allopurinol | 85 | suppressed |
| Nystop | Nystatin | 85 | 14 |
| Finasteride | Finasteride | 82 | suppressed |
| Carvedilol | Carvedilol | 81 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | suppressed |
| Prednisone | Prednisone | 75 | 35 |
| Xarelto | Rivaroxaban | 75 | suppressed |
| Memantine Hcl | Memantine Hcl | 73 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 65 | suppressed |
| Risperidone | Risperidone | 62 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Latanoprost | Latanoprost | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | suppressed |
| Lactulose | Lactulose | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 49 | suppressed |
| Ssd | Silver Sulfadiazine | 48 | 11 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 39 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 39 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 36 |
| Omeprazole | Omeprazole | 35 | 12 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 19 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 15 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 24 |
| Methylprednisolone | Methylprednisolone | 24 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Rytary | Carbidopa/Levodopa | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 17 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Azithromycin | Azithromycin | 13 | 13 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | 13 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Ongentys | Opicapone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | 11 |
| Phenytoin | Phenytoin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $765.56 · 24 records | ABBVIE INC. | AVYCAZ, CALDOLOR, COLLAGENASE SANTYL, DALVANCE, ELIQUIS, EMBLAVEO, JOURNAVX, REXULTI, TEFLARO, ZERBAXA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error